Media Release - First patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a...
Read More
First patient dosed in SCENESSE® DNA Repair Program
Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced...
Read More
Media Release (ASX) - CLINUVEL progresses innovative DNA Repair Program
Drug tested to protect skin and regenerate DNA, firstly in XP patients...
Read More
Media Release – New drug to repair damaged skin and reduce skin cancer risk
Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with...
Read More
SCENESSE® in DNA Repair
CLINUVEL to confirm cellular DNA repair in rare disease xeroderma pigmentosum (XP)...
Read More
Media Release - Second Afamelanotide Formulation
PRÉNUMBRA®- CLINUVEL’S SECOND AFAMELANOTIDE FORMULATION Drug to be evaluated in patients with...
Read More
PRÉNUMBRA® – New Liquid Afamelanotide Presentation
EXECUTIVE SUMMARY• PRÉNUMBRA® non-solid dosage form of afamelanotide• Active life-cycle management of...
Read More
Request for FDA Guidance Meeting SCENESSE® in Vitiligo
CLINUVEL requests Type C Guidance meeting to progress the clinical program in...
Read More
Australian TGA commences SCENESSE® review
EXECUTIVE SUMMARY SCENESSE® (afamelanotide 16mg) technology review starts in Australia for rare...
Read More